Market Place
Sourcing Support
Ollin to Share 20-Week OLN324 vs Faricimab Head-to-Head Eye Data
02 Jun 2026 //
BUSINESSWIRE
Ollin Biosciences to Present at Investor Conferences
27 May 2026 //
BUSINESSWIRE
Ollin Bio to Participate in Two Upcoming Investor Conferences
08 Apr 2026 //
BUSINESSWIRE
Ollin Bio OLN324 Beats Vabysmo Wet AMD DME Study Data
30 Mar 2026 //
BUSINESSWIRE
Ollin Shows Superior Results vs Vabysmo in Eye Disease Study
08 Jan 2026 //
BUSINESSWIRE
Ollin Eyes Phase 3 After Topping Vabysmo In Early-Stage Trial
08 Jan 2026 //
FIERCE BIOTECH
Ollin Biosciences Presents at 44th J.P. Morgan Healthcare Conf
18 Dec 2025 //
BUSINESSWIRE
Addition Debuts $100M Fund for Rare Disease One-Time Therapies
17 Dec 2025 //
BIOSPACE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.